LQDA Quote, Financials, Valuation and Earnings

ANI Pharmaceuticals, Inc. has a net margin of -6.5% compared to Liquidia Corp.'s net margin of 10.59%. Liquidia Corp.'s return on equity of -221.75% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.

Liquidia Corp. has a consensus price target of $43.00, signalling upside risk potential of 28.01%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $110.50 which suggests that it could grow by 42.09%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than Liquidia Corp., analysts believe ANI Pharmaceuticals, Inc. is more attractive than Liquidia Corp..

Liquidia Corp. has a beta of 0.463, which suggesting that the stock is 53.687% less volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.500, suggesting its less volatile than the S&P 500 by 50.037%.

Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia Corp. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Liquidia Corp. quarterly revenues are $54.3M, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. Liquidia Corp.'s net income of -$3.5M is lower than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while ANI Pharmaceuticals, Inc.'s PE ratio is 47.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 41.47x versus 1.90x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Curis, Inc. has a net margin of -6.5% compared to Liquidia Corp.'s net margin of -243.36%. Liquidia Corp.'s return on equity of -221.75% beat Curis, Inc.'s return on equity of -461.34%.

Liquidia Corp. has a consensus price target of $43.00, signalling upside risk potential of 28.01%. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 1161.26%. Given that Curis, Inc. has higher upside potential than Liquidia Corp., analysts believe Curis, Inc. is more attractive than Liquidia Corp..

Liquidia Corp. has a beta of 0.463, which suggesting that the stock is 53.687% less volatile than S&P 500. In comparison Curis, Inc. has a beta of 3.078, suggesting its more volatile than the S&P 500 by 207.818%.

Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia Corp. pays -- of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.

Liquidia Corp. quarterly revenues are $54.3M, which are larger than Curis, Inc. quarterly revenues of $3.2M. Liquidia Corp.'s net income of -$3.5M is higher than Curis, Inc.'s net income of -$7.7M. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 41.47x versus 1.06x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Indivior Pharmaceuticals, Inc. has a net margin of -6.5% compared to Liquidia Corp.'s net margin of 13.38%. Liquidia Corp.'s return on equity of -221.75% beat Indivior Pharmaceuticals, Inc.'s return on equity of 14.29%.

Liquidia Corp. has a consensus price target of $43.00, signalling upside risk potential of 28.01%. On the other hand Indivior Pharmaceuticals, Inc. has an analysts' consensus of $45.57 which suggests that it could grow by 34.47%. Given that Indivior Pharmaceuticals, Inc. has higher upside potential than Liquidia Corp., analysts believe Indivior Pharmaceuticals, Inc. is more attractive than Liquidia Corp..

Liquidia Corp. has a beta of 0.463, which suggesting that the stock is 53.687% less volatile than S&P 500. In comparison Indivior Pharmaceuticals, Inc. has a beta of 1.134, suggesting its more volatile than the S&P 500 by 13.42%.

Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Indivior Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia Corp. pays -- of its earnings as a dividend. Indivior Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Liquidia Corp. quarterly revenues are $54.3M, which are smaller than Indivior Pharmaceuticals, Inc. quarterly revenues of $314M. Liquidia Corp.'s net income of -$3.5M is lower than Indivior Pharmaceuticals, Inc.'s net income of $42M. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while Indivior Pharmaceuticals, Inc.'s PE ratio is 33.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 41.47x versus 3.63x for Indivior Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -6.5% compared to Liquidia Corp.'s net margin of 18.06%. Liquidia Corp.'s return on equity of -221.75% beat Merck & Co., Inc.'s return on equity of 39.63%.

Liquidia Corp. has a consensus price target of $43.00, signalling upside risk potential of 28.01%. On the other hand Merck & Co., Inc. has an analysts' consensus of $126.00 which suggests that it could grow by 3.06%. Given that Liquidia Corp. has higher upside potential than Merck & Co., Inc., analysts believe Liquidia Corp. is more attractive than Merck & Co., Inc..

Liquidia Corp. has a beta of 0.463, which suggesting that the stock is 53.687% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Liquidia Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.68% to investors and pays a quarterly dividend of $0.85 per share. Liquidia Corp. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Liquidia Corp. quarterly revenues are $54.3M, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Liquidia Corp.'s net income of -$3.5M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Liquidia Corp.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 16.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia Corp. is 41.47x versus 4.72x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.